LONDON: Oxford University’s Covid-19 candidate vaccine has a better immune response when using a two-full-dose regimen rather than a full dose followed by a half-dose booster, the university said Thursday, citing data from the first trials.
The developers of the candidate vaccine, which has been licensed to the pharmaceutical company AstraZeneca, have already published results from later-stage trials showing greater efficacy when a half dose is followed by a full dose, compared to a two-dose regimen. complete. However, more work is needed to affirm that result.
The latest details from Phase I and 2 clinical trials released Thursday made no reference to the half-dose / full-dose regimen, which Oxford has said was not “planned” but approved by regulators.
Once seen as the pioneer in the development of a coronavirus vaccine, the British team has been overtaken by US drugmaker Pfizer, whose vaccines have been rolled out in the UK and US this month.
Previously published data from the latest Phase 3 trials showed that efficacy was 62% for trial participants who received two full doses, but 90% stronger for a smaller subgroup that received half and then one dose. complete.
In its statement Thursday, the university said it had explored two dosing regimens in the early stages of the trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, investigated as a possible “savings strategy. dose “.
“Booster doses of the vaccine have been shown to induce stronger antibody responses than a single dose, and the standard dose / standard dose induces the best response,” the university said in a statement.
The vaccine “stimulates broad antibody and T-cell functions,” he said.
The developers of the candidate vaccine, which has been licensed to the pharmaceutical company AstraZeneca, have already published results from later-stage trials showing greater efficacy when a half dose is followed by a full dose, compared to a two-dose regimen. complete. However, more work is needed to affirm that result.
The latest details from Phase I and 2 clinical trials released Thursday made no reference to the half-dose / full-dose regimen, which Oxford has said was not “planned” but approved by regulators.
Once seen as the pioneer in the development of a coronavirus vaccine, the British team has been overtaken by US drugmaker Pfizer, whose vaccines have been rolled out in the UK and US this month.
Previously published data from the latest Phase 3 trials showed that efficacy was 62% for trial participants who received two full doses, but 90% stronger for a smaller subgroup that received half and then one dose. complete.
In its statement Thursday, the university said it had explored two dosing regimens in the early stages of the trials, a full-dose / full-dose regimen and a full-dose / half-dose regimen, investigated as a possible “savings strategy. dose “.
“Booster doses of the vaccine have been shown to induce stronger antibody responses than a single dose, and the standard dose / standard dose induces the best response,” the university said in a statement.
The vaccine “stimulates broad antibody and T-cell functions,” he said.
.
